Dextromethorphan/quinidine

Dextromethorphan/quinidine

Identifiers
IUPAC name (+)-3-methoxy-17-methyl-(9α,13α,14α)-morphinan and (S)-(6-methoxyquinolin-4-yl)((2R,4S,8R)-8-vinylquinuclidin-2-yl)methanol

NUEDEXTA is the first FDA-approved drug for the treatment of Pseudobulbar affect. It is a combination product containing dextromethorphan 12 hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 13 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor).

Mechanism of Action Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown.

Pharmacokinetics NUEDEXTA contains dextromethorphan and quinidine, both of which are metabolized primarily by liver enzymes. Quinidine’s primary pharmacological action in NUEDEXTA is to competitively inhibit the metabolism of dextromethorphan catalyzed by CYP2D6 in order to increase and prolong plasma concentrations of dextromethorphan. Studies were conducted with the individual components of NUEDEXTA in healthy subjects to determine single-dose and multiple-dose kinetics of orally administered dextromethorphan hydrobromide in combination with quinidine sulfate. The increase in dextromethorphan levels appeared approximately dose proportional when the dextromethorphan hydrobromide dose increased from 20 mg to 30 mg in the presence of 10 mg of quinidine sulfate.

Interactions

• Desipramine levels increase 8-fold with co-administration
• Paroxetine
• Memantine